HomeATAI • NASDAQ
ATAI Life Sciences NV
$1.65
After Hours:
$1.62
(1.70%)-0.028
Closed: May 16, 7:10:43 PM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$1.63
Day range
$1.63 - $1.76
Year range
$1.03 - $2.57
Market cap
329.66M USD
Avg Volume
1.46M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Mar 2025Y/Y change
Revenue
1.56M
Operating expense
21.92M-1.17%
Net income
-26.43M1.06%
Net profit margin
-1.70K
Earnings per share
-0.1511.76%
EBITDA
-20.25M8.37%
Effective tax rate
-0.59%
Total assets
Total liabilities
(USD)Mar 2025Y/Y change
Cash and short-term investments
98.20M-7.57%
Total assets
195.78M-27.25%
Total liabilities
43.51M-5.13%
Total equity
152.27M
Shares outstanding
176.27M
Price to book
1.90
Return on assets
-28.68%
Return on capital
-31.59%
Net change in cash
(USD)Mar 2025Y/Y change
Net income
-26.43M1.06%
Cash from operations
Cash from investing
Cash from financing
Net change in cash
Free cash flow
About
atai Life Sciences is a pharmaceutical company that is developing psychedelics, other hallucinogens, entactogens, and related drugs for treatment of psychiatric conditions. It was founded in 2018 and is headquartered in Berlin, Germany. The company's pharmaceutical candidates include dimethyltryptamine, -midomafetamine, and ibogaine, as well as EGX-121, 5-MeO-DMT, psilocin, inidascamine, deuterated mitragynine, EGX-A, EGX-B, deuterated etifoxine, and arketamine. In June 2021, atai became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In January 2023, atai Life Science's leading drug candidate at the time, arketamine, failed to meet its primary endpoint in a clinical trial. Following that, the company laid off 30% of its staff. Peter Thiel is a major investor in the company. atai Life Sciences has a 22.4% stake in Compass Pathways. Wikipedia
Founded
2018
Website
Employees
54
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu